newsfilter
← Latest News
Business Wire·

Atara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

Prescription Drug User Fee Act (PDUFA) Target Action Date of March 31, 2027 If Approved, Tab-cel Would Be the First Therapy Available in the U.S. for EBV+ PTLD Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in